Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments

Epcoritamab (Tepkinly, AbbVie) is indicated for 'adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy'.

The dosage schedule is available in the summary of product characteristics for epcoritamab 4-mg/0.8 ml concentrate for solution for injection and epcoritamab 48-mg solution for injection.

The list price for epcoritamab is £6,568 per 48‑mg vial and £547.33 per 4‑mg vial (excluding VAT; company submission).

The company has a commercial arrangement. This makes epcoritamab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.